TRIM21 and systemic sclerosis: Anti-centromere, or none of the tested autoantibodies (anti-TRIM21 included) had numerically lower risks of developing cancer within two years in the cohort of SSc.Anti-Topo I and anti-U1-RNP associated with cancer risk within two years of scleroderma onset.